Researchers are reporting promising results from a small study examining a new approach to HIV treatment that could potentially suppress the virus for years with a single infusion. The study, scheduled to be presented this week, involves a type of therapy that has previously shown success in treating certain blood cancers.

The research represents a significant development in HIV treatment, though details about the number of patients involved and specific mechanisms remain limited as the full study has not yet been published. Current HIV treatments typically require daily medication to maintain viral suppression.

Meanwhile, health researchers are raising concerns about marketing claims surrounding NAD+ supplements, a compound being promoted by wellness and longevity influencers as having anti-aging properties. Scientists acknowledge there is legitimate research interest in NAD+ and its potential health benefits, but they warn that commercial marketing claims have outpaced the available scientific evidence.

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found naturally in cells that plays a role in energy metabolism. Companies are selling NAD+ in pill form and as infusions, often with promises about extending lifespan and improving health, despite limited clinical data supporting such broad claims.

Researchers emphasize the need for more rigorous clinical trials before drawing conclusions about NAD+'s effectiveness for longevity applications. The gap between preliminary research and marketing claims highlights ongoing challenges in the supplement industry, where products can be sold without the same level of regulatory oversight required for prescription medications.